| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥299.86B | ¥214.86B | +39.6% |
| Cost of Sales | ¥251.47B | ¥184.76B | +36.1% |
| Gross Profit | ¥48.39B | ¥30.10B | +60.8% |
| SG&A Expenses | ¥37.87B | ¥24.22B | +56.3% |
| Operating Income | ¥10.52B | ¥5.87B | +79.1% |
| Non-operating Income | ¥943M | ¥760M | +24.1% |
| Non-operating Expenses | ¥1.55B | ¥293M | +428.0% |
| Ordinary Income | ¥9.91B | ¥6.34B | +56.4% |
| Profit Before Tax | ¥9.61B | ¥6.73B | +42.9% |
| Income Tax Expense | ¥5.09B | ¥3.52B | +44.5% |
| Net Income | ¥4.52B | ¥3.20B | +41.0% |
| Net Income Attributable to Owners | ¥4.49B | ¥3.21B | +39.9% |
| Total Comprehensive Income | ¥4.98B | ¥3.34B | +48.9% |
| Depreciation & Amortization | ¥5.07B | ¥3.71B | +36.5% |
| Interest Expense | ¥882M | ¥84M | +950.0% |
| Earnings per Unit (EPU) | ¥128.05 | ¥91.75 | +39.6% |
| Distribution per Unit (DPU) | ¥0.00 | ¥0.00 | - |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥174.84B | ¥112.81B | +¥62.04B |
| Cash and Deposits | ¥53.15B | ¥26.88B | +¥26.27B |
| Accounts Receivable | ¥43.87B | ¥22.30B | +¥21.57B |
| Inventories | ¥45.32B | ¥35.57B | +¥9.75B |
| Non-current Assets | ¥339.72B | ¥199.11B | +¥140.61B |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥1.23B | ¥12.73B | ¥-11.50B |
| Investing Cash Flow | ¥-53.21B | ¥-54.05B | +¥834M |
| Financing Cash Flow | ¥78.18B | ¥20.14B | +¥58.05B |
| Free Cash Flow | ¥-51.99B | - | - |
| Item | Value |
|---|---|
| Net Profit Margin | 1.5% |
| Gross Profit Margin | 16.1% |
| Current Ratio | 54.8% |
| Quick Ratio | 40.6% |
| Debt-to-Equity Ratio | 2.54x |
| Interest Coverage Ratio | 11.92x |
| EBITDA Margin | 5.2% |
| Effective Tax Rate | 53.0% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +39.6% |
| Operating Income YoY Change | +79.1% |
| Ordinary Income YoY Change | +56.4% |
| Net Income Attributable to Owners YoY Change | +39.9% |
| Total Comprehensive Income YoY Change | +48.9% |
| Item | Value |
|---|---|
| Units Outstanding (incl. Treasury) | 35.43M shares |
| Treasury Units | 310K shares |
| Average Units Outstanding | 35.10M shares |
| NAV per Unit | ¥4,142.81 |
| EBITDA | ¥15.58B |
| Item | Amount |
|---|---|
| Q2 Distribution | ¥0.00 |
| Year-End Distribution | ¥80.00 |
| Segment | Revenue |
|---|---|
| DispensingPharmacy | ¥254.74B |
| DrugAndCosmeticStore | ¥39.57B |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥646.00B |
| Operating Income Forecast | ¥28.30B |
| Ordinary Income Forecast | ¥26.50B |
| Net Income Attributable to Owners Forecast | ¥13.50B |
| Earnings per Unit Forecast (EPU) | ¥384.91 |
| Distribution per Unit Forecast (DPU) | ¥80.00 |
| Property, Plant & Equipment | ¥61.70B | ¥49.71B | +¥11.98B |
| Intangible Assets | ¥215.40B | ¥97.62B | +¥117.78B |
| Goodwill | ¥201.60B | ¥84.77B | +¥116.83B |
| Investment Securities | ¥4.25B | ¥3.23B | +¥1.01B |
| Total Assets | ¥514.57B | ¥311.92B | +¥202.65B |
| Current Liabilities | ¥319.00B | ¥132.04B | +¥186.96B |
| Accounts Payable | ¥110.30B | ¥80.89B | +¥29.41B |
| Short-term Loans | ¥160.60B | ¥12.15B | +¥148.45B |
| Non-current Liabilities | ¥50.08B | ¥37.24B | +¥12.84B |
| Long-term Loans | ¥35.12B | ¥26.47B | +¥8.65B |
| Total Liabilities | ¥369.08B | ¥169.29B | +¥199.79B |
| Total Equity | ¥145.49B | ¥142.63B | +¥2.85B |
| Capital Stock | ¥21.89B | ¥21.89B | ¥0 |
| Capital Surplus | ¥20.13B | ¥20.13B | +¥1M |
| Retained Earnings | ¥103.36B | ¥101.69B | +¥1.67B |
| Treasury Stock | ¥-1.75B | ¥-2.00B | +¥248M |
| Owners' Equity | ¥144.90B | ¥142.52B | +¥2.38B |
| Working Capital | ¥-144.16B | - | - |